open access

Vol 44, No 6 (2010)
Submitted: 2010-07-14
Get Citation

Interleukin-6 gene –174 C/G and apolipoprotein E gene polymorphisms and the risk of Alzheimer disease in a Polish population

Aleksandra Klimkowicz-Mrowiec, Paweł Wotkow, Karolina Spisak, Aleksandra Maruszak, Maria Styczyńska, Maria Barcikowska, Andrzej Szczudlik, Agnieszka Słowik
DOI: 10.1016/S0028-3843(14)60149-3
·
Neurol Neurochir Pol 2010;44(6):537-541.

open access

Vol 44, No 6 (2010)
Submitted: 2010-07-14

Abstract

Background and purpose

Inflammation plays a prominent role in Alzheimer disease (AD) pathogenesis. Interleukin-6 (IL-6), a pro-inflammatory cytokine, and some genetic variations in the IL-6 gene have been reported to be associated with a risk of AD. However, the results of the conducted studies are equivocal.

Material and methods

We genotyped IL-6 (–174 C/G) and apolipoprotein E gene (APOE) common polymorphisms in a large case-controlled study in a Polish population. We included 361 patients aged ≥ 65 years with AD (mean age 75.8 ± 5.3 years, 232 females [64.3%]) and 200 controls (75.3 ± 7.4 years; 119 females [59.5%]), without any neurological deficit, cognitive complaints or history of neurological diseases. The IL-6 polymorphism was genotyped using TaqMan SNP allelic discrimination by means of an ABI 7900HT (Applied Biosystems, Foster City, CA).

Results

The distribution of the IL-6 (–174 C/G) genotypes was similar to that in the controls (AD: C/C = 15.79%, C/G = 51.25%, G/G = 32.96% vs. controls: C/C = 21.50%, C/G = 45.50%, G/G = 33.0%, p > 0.05). Our study confirms previous reports that APOE 4 is strongly related to the risk of AD (OR = 6.17; 95% CI: 4.01–9.49). APOE status did not affect the distribution of the studied IL-6 polymorphism.

Conclusion

IL-6 (–174 C/G) polymorphism is not a risk factor for late onset AD in a Polish population.

Abstract

Background and purpose

Inflammation plays a prominent role in Alzheimer disease (AD) pathogenesis. Interleukin-6 (IL-6), a pro-inflammatory cytokine, and some genetic variations in the IL-6 gene have been reported to be associated with a risk of AD. However, the results of the conducted studies are equivocal.

Material and methods

We genotyped IL-6 (–174 C/G) and apolipoprotein E gene (APOE) common polymorphisms in a large case-controlled study in a Polish population. We included 361 patients aged ≥ 65 years with AD (mean age 75.8 ± 5.3 years, 232 females [64.3%]) and 200 controls (75.3 ± 7.4 years; 119 females [59.5%]), without any neurological deficit, cognitive complaints or history of neurological diseases. The IL-6 polymorphism was genotyped using TaqMan SNP allelic discrimination by means of an ABI 7900HT (Applied Biosystems, Foster City, CA).

Results

The distribution of the IL-6 (–174 C/G) genotypes was similar to that in the controls (AD: C/C = 15.79%, C/G = 51.25%, G/G = 32.96% vs. controls: C/C = 21.50%, C/G = 45.50%, G/G = 33.0%, p > 0.05). Our study confirms previous reports that APOE 4 is strongly related to the risk of AD (OR = 6.17; 95% CI: 4.01–9.49). APOE status did not affect the distribution of the studied IL-6 polymorphism.

Conclusion

IL-6 (–174 C/G) polymorphism is not a risk factor for late onset AD in a Polish population.

Get Citation

Keywords

Alzheimer disease, interleukin-6, APOE, polymorphism, risk factor, Polish population

About this article
Title

Interleukin-6 gene –174 C/G and apolipoprotein E gene polymorphisms and the risk of Alzheimer disease in a Polish population

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 44, No 6 (2010)

Pages

537-541

DOI

10.1016/S0028-3843(14)60149-3

Bibliographic record

Neurol Neurochir Pol 2010;44(6):537-541.

Keywords

Alzheimer disease
interleukin-6
APOE
polymorphism
risk factor
Polish population

Authors

Aleksandra Klimkowicz-Mrowiec
Paweł Wotkow
Karolina Spisak
Aleksandra Maruszak
Maria Styczyńska
Maria Barcikowska
Andrzej Szczudlik
Agnieszka Słowik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl